# Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

> **NCT05976997** · PHASE2 · RECRUITING · sponsor: **Liling Zhang** · enrollment: 36 (estimated)

## Conditions studied

- Newly Diagnosed Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Duvelisib, Chidamide

## Key facts

- **NCT ID:** NCT05976997
- **Lead sponsor:** Liling Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976997, "Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT05976997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*